News

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric…

6 days ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in…

6 days ago

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira…

6 days ago

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading…

6 days ago

NervGen Announces “At-The-Market” Equity Program

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a…

6 days ago

Prytime Medical Announces Key Prolonged REBOA Advancements to Treat Maternal Hemorrhage

BOERNE, Texas, Dec. 20, 2024 /PRNewswire/ -- Prytime Medical, The REBOA Company™, is proud to announce significant strides made in…

6 days ago

ZuriMED Secures FDA Clearance for the FiberLocker(R) System

BOSTON, MA / ZURICH, SWITZERLAND / ACCESSWIRE / December 20, 2024 / The Swiss MedTech startup ZuriMED Technologies AG is…

6 days ago

Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…

6 days ago

FendX Announces RSU Grant

Oakville, Ontario--(Newsfile Corp. - December 19, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or…

7 days ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in…

7 days ago